High-impact paper: optimal revascularization of patients with chronic coronary artery disease
Associate Professor and Consultant Cardiac Surgeon Ivy Susanne Modrau from our department contributed to the FAME 3 trial, where the results from the multicenter study recently was published in New England Journal of Medicine (NEJM): Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery.
New evidence regarding optimal revascularization of patients with chronic coronary artery disease was published today in the New England Journal of Medicine: Fractional Flow Reserve–Guided PCI as Compared with Coronary Bypass Surgery.
In the FAME 3 trial, 1500 patients with three-vessel coronary artery disease from 48 centres (Europe, US & Australia) were randomly assigned to undergo CABG or FFR-guided PCI with current-generation zotarolimus-eluting stents. It was hypothesized that PCI was non-inferior to CABG with respect to the incidence of a composite endpoint of death, myocardial infarction, stroke, or repeat revascularization at 1 year. However, PCI patients were shown to have inferior outcome after 1 year despite usage of state of the art technology (incidence of composite primary endpoint: PCI 10.6% versus CABG 6.9%; hazard ratio, 1.5; 95% confidence interval 1.1-2.2).
Aarhus University Hospital is proud to have contributed to this important study which will influence future guideline recommendations.
Contact
Ivy Susanne Modrau
Associate Professor, Consultant
Division of Cardiac Surgery
Department of Cardiothoracic and Vascular Surgery
Aarhus University Hospital
Palle Juul-Jensens Boulevard 99
DK-8200 Aarhus N
Mail: ivymod@clin.au.dk